The study will start now and run in parallel with Recce’s Indonesian Phase 3 trial, which remains on track to commence shortly. This program does not impact the initiation timeline of the ...

SYDNEY, April 23, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), a leading developer of a new class of synthetic anti-infectives, today announced ...